BridgeMD
New treatment option for Symptomatic Irreversible Pulpitis
Official title The Effect of XP-Endo Finisher Activation of Bioceramic Sealer on Postoperative Pain in Mandibular First Molar With Symptomatic Irreversible Pulpitis
ClinicalTrials.gov ID: NCT06640231
What this study is testing
- What it's testing
- The aim of endodontic obturation is to make a complete sealing along the length of the root canal system to ensuring the peri radicular tissue healing and sustained health. Disadvantages of gutta-percha-based root filling materials is lack of adhesiveness to canal wall dentin.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 40. Healthy volunteers may be eligible.
You may be able to join if
- Age ranges from 18 to 40 years old.
- No sex predilection.
- Patients seeking root canal treatment.
- Systematically healthy patient (ASA I, II).
- Patient who can understand numerical rate scale and sign an informed consent.
You likely can't join if
- Patients with American association of anesthesiologists (ASA) classification other than ASA T\& II.
- Patients who have already ingested preoperative medication, such as analgesics, non-steroidal or steroidal anti-inflammatory drugs, within 12 hours...
- Patients with NSAIDs allergy.
- Patients having two or more adjacent teeth needing root canal therapy.
- Pregnant patients.
- Patients with bleeding disorder.
See the full eligibility criteria
- Age ranges from 18 to 40 years old.
- No sex predilection.
- Patients seeking root canal treatment.
- Systematically healthy patient (ASA I, II).
- Patient who can understand numerical rate scale and sign an informed consent.
- Mandibular first molar teeth with:
- Preoperative sharp (moderate or severe) pain.
- Vital response of pulp tissue to cold pulp tester (ethyl chloride spray).
- Normal periapical radiographic appearance.
- Patients with American association of anesthesiologists (ASA) classification other than ASA T\& II.
- Patients who have already ingested preoperative medication, such as analgesics, non-steroidal or steroidal anti-inflammatory drugs, within 12 hours of the start of treatment.
- Patients with NSAIDs allergy.
- Patients having two or more adjacent teeth needing root canal therapy.
- Pregnant patients.
- Patients with bleeding disorder.
- Patients with long term corticosteroid use
- Teeth having;
- Necrotic pulp.
- History or presence of swelling or fistulous tract.
- Acute / chronic periapical abscess.
- Mobility more than grade 1.
- Pocket depth more than 5mm.
- No possible restorability.
- Previous root canal treatment.
- Periapical radiolucency.
- External or internal resorption.
- Vertical root fracture.
- TMJ problems, bruxism, clenching or traumatic occlusion.
- Inability to understand and perform the given instructions.
The study team makes the final eligibility decision.
Where it's taking place
- Cairo, New Cairo, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 40 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Cairo, New Cairo, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.